Fractalkine/CX3CR1 and atherosclerosis

Area of Science:

• Cardiovascular biology
• Immunology
• Molecular medicine

Background:

• Inflammation is crucial in atherosclerosis pathogenesis.
• Chemokines, like fractalkine (CX3CL1), are increasingly recognized for their roles in cardiovascular disease.
• Fractalkine/CX3CR1 signaling influences leukocyte recruitment and vascular cell interactions in atherosclerosis.

Purpose of the Study:

• To review the multifaceted role of the fractalkine/CX3CR1 axis in atherosclerosis.
• To highlight fractalkine's impact on vascular inflammation, plaque stability, and cellular processes.
• To discuss the implications of fractalkine/CX3CR1 in atherosclerotic disease risk and progression.

Main Methods:

• Literature review of studies investigating fractalkine/CX3CR1 in atherosclerosis.
• Analysis of experimental data from animal models of atherosclerosis.
• Examination of human population studies on CX3CR1 polymorphisms.

Main Results:

• Fractalkine/CX3CR1 mediates leukocyte recruitment and vascular cell interactions, promoting inflammation in atherosclerotic vessels.
• Fractalkine exhibits cytotoxic, anti-apoptotic, and proliferative effects on vascular cells, altering plaque characteristics.
• Genetic deficiency or specific polymorphisms in CX3CR1 are associated with ameliorated plaque severity and reduced atherosclerotic disease risk.

Conclusions:

• The fractalkine/CX3CR1 system is a significant contributor to atherosclerotic pathology.
• Targeting the fractalkine/CX3CR1 pathway may offer therapeutic strategies for atherosclerosis.
• Further research is essential to fully understand and leverage the fractalkine/CX3CR1 relationship in cardiovascular disease.